Market Closed -
Japan Exchange
02:00:00 2024-05-24 am EDT
5-day change
1st Jan Change
395
JPY
-0.75%
-3.19%
-25.47%
Linical Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2021
August 12, 2021 at 04:05 am EDT
Linical Co., Ltd. reported consolidated earnings results for the first quarter ended June 30, 2021. For the quarter, the company reported net sales of JPY 2,784 million compared to JPY 2,424 million a year ago. Operating income was JPY 145 million compared to loss of JPY 150 million a year ago. Profit was JPY 67,651,000 compared to loss of JPY 199,416,000 million a year ago. Net income per share was JPY 3.00 against loss of JPY 8.83 a year ago.
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 12, 2024; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2025
May. 15
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025
May. 15
CI
Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Apr. 12
CI
Linical Cuts Revenue, Earnings Forecast on Lower-Than-Expected Sales, Extraordinary Losses
Feb. 21
MT
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
Feb. 14
CI
Linical Seeks Listing on Standard Market Following Revised Tokyo Stock Exchange Rules
23-09-26
MT
Linical Co., Ltd. Provides Dividend Forecast for the Year Ending March 31, 2024
23-08-14
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
23-08-14
CI
Linical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-15
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
23-05-15
CI
Linical Co., Ltd. Provides Year Ending Dividend Forecast for the Year Ending March 31, 2024
23-05-15
CI
Linical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023
23-05-15
CI
Linical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023
23-02-14
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
23-02-14
CI
Linical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023
22-12-27
CI
Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2023
22-12-27
CI
Science 37 Holdings, Linical Americas to Deploy Decentralized Clinical Trial Services
22-11-17
MT
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-11-14
CI
Linical Co., Ltd.(TSE:2183) dropped from S&P Global BMI Index
22-09-19
CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
22-08-12
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-08-12
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-05-16
CI
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 9, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
22-05-16
CI
Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022
22-02-14
CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022
22-02-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.
More about the company
1st Jan change
Capi.
-25.47% 56.85M +67.53% 63.85B -0.77% 41.83B +45.66% 40.65B -10.72% 27.12B +13.30% 26.52B -22.79% 18.69B +4.70% 12.73B +24.10% 12.11B +27.41% 12.07B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1